RELEASE AND PERMEATION STUDIES OF PROPRANOLOL HYDROCHLORIDE FROM HYDROPHILIC POLYMERIC MATRICES

被引:6
作者
BABAR, A
PILLAI, J
PLAKOGIANNIS, FM
机构
[1] Division of Pharmaceutics and Industrial Pharmacy, Arnold and Marie Schwartz College of Pharmacy Long Island University, Brooklyn, NY
关键词
D O I
10.3109/03639049209040905
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In-vitro release of propranolol hydrochloride, from various hydrophilic polymeric bases was studied. These included: methocel(R), avicel(R) CL-611/ methylcellulose, polyvinyl alcohol/gelatin based systems. Several additives, such as, ethyl alcohol, dimethylsulfoxide (DMSO) and polyethylene glycol-400 were included in the formulations for possible enhancement of the drug release. The release studies were carried out using the cellulose membrane and the hairless mouse skin as the diffusion barriers. The general rank order for the drug release through these membranes was observed to be: the methocel(R) matrix > the avicel(R) CL-611 matrix > the polyvinyl alcohol/gelatin matrix > and the emulsion base. The additives in the formulations had little or no effect in enhancing the drug release. However, when the hairless mouse skin was soaked in (DMSO) for one hour prior to its use in the diffusion studies, the drug release was found to increase by 40% from the methocel(R) matrix formulation. The drug release data were treated with various kinetic principles to assess the relevant parameters, such as the diffusion, partition and permeability coefficients. Using these information, the formulations were screened for their suitability to deliver propranolol hydrochloride via the diadermatic dosage form.
引用
收藏
页码:1823 / 1830
页数:8
相关论文
共 16 条
[1]   PIROXICAM RELEASE FROM DERMATOLOGICAL BASES - INVITRO STUDIES USING CELLULOSE MEMBRANE AND HAIRLESS MOUSE SKIN [J].
BABAR, A ;
SOLANKI, UD ;
CUTIE, AJ ;
PLAKOGIANNIS, F .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1990, 16 (03) :523-540
[2]   COMPARISON OF SOME PROPERTIES OF PRONETHALOL AND PROPRANOLOL [J].
BLACK, JW ;
DUNCAN, WAM ;
SHANKS, RG .
BRITISH JOURNAL OF PHARMACOLOGY AND CHEMOTHERAPY, 1965, 25 (03) :577-+
[3]  
BLACK JW, 1964, LANCET, V1, P1080
[4]   STUDIES OF ABSORPTION AND REMOVAL OF PROPRANOLOL IN HYPERTENSIVE PATIENTS DURING THERAPY [J].
CHIDSEY, CA ;
MORSELLI, P ;
BIANCHETTI, G ;
MORGANTI, A ;
LEONETTI, G ;
ZANCHETTI, A .
CIRCULATION, 1975, 52 (02) :313-318
[5]   PHARMACOKINETICS OF PROPRANOLOL IN NORMAL HEALTHY VOLUNTEERS [J].
GOMENI, R ;
BIANCHETTI, G ;
SEGA, R ;
MORSELLI, PL .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1977, 5 (03) :183-192
[7]   PROPRANOLOL IN TREATMENT OF HYPERTENSION [J].
HOLLAND, OB ;
KAPLAN, NM .
NEW ENGLAND JOURNAL OF MEDICINE, 1976, 294 (17) :930-936
[8]   NASAL ABSORPTION OF PROPRANOLOL IN HUMANS [J].
HUSSAIN, A ;
FOSTER, T ;
HIRAI, S ;
KASHIHARA, T ;
BATENHORST, R ;
JONES, M .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1980, 69 (10) :1240-1240
[9]  
PATERSON JW, 1966, LANCET, V2, P1148
[10]   PROPRANOLOL IN HYPERTENSION [J].
PRICHARD, BN ;
GILLAM, PMS .
AMERICAN JOURNAL OF CARDIOLOGY, 1966, 18 (03) :387-+